The phase 1b trial is investigating the ADC and Keytruda – with or without chemo – in both previously-untreated and pretreated patients with advanced NSCLC who don’t have genetic mutations ...
Safeguard access for any identity, anywhere, to AI, apps, and resources across on-premises and clouds with a unified identity and network access solution. Automate identity governance to give any user ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback